Access Barriers to Pembrolizumab in Brazil
This cross-sectional study examines the lawsuits that followed national and international policies for pembrolizumab approval.
Authors
- Mitesh J. Borad (ORCID: https://orcid.org/0000-0003-2700-2658)
- Guilherme Andriatte
- Francisco Tustumi (ORCID: https://orcid.org/0000-0001-6695-0496)
- Flávio Tocci Moreira (ORCID: https://orcid.org/0000-0001-6574-3866)
- Manuel Teixeira (ORCID: https://orcid.org/0000-0001-6364-0011)
- Pedro Luiz Serrano Usón (ORCID: https://orcid.org/0000-0001-6122-1374)
- Carlos Henrique Sartorato Pedrotti (ORCID: https://orcid.org/0000-0002-0634-7086)
- Fernando Silva de Moura (ORCID: https://orcid.org/0000-0002-0433-1224)
- Uelson Donizeti Rocioli
- Isabella Sforzin
Institutions
- Hospital Israelita Albert Einstein (BR)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.28585
- Primary Topic
- Public Health in Brazil
- Type
- article
- Field-Weighted Citation Impact
- 0.00